EMA clears Biocon's new Semglee fill line in Malaysia
European nod expands capacity for biosimilar insulin glargine at Johor plant; shipments to begin Q2 FY27, financial impact undisclosed.
— 2 earlier stories on Biocon Ltd. →What's new
- EMA approved a new fill finish line for Semglee at Biocon's Johor plant.
- Shipments to Europe expected to start in Q2 FY27.
- Semglee already marketed in EU as a cheaper alternative to Lantus.
Why this matters
The approval de-risks EU supply for Biocon's key insulin product. But with no capacity or revenue disclosed, the near-term impact is modest, especially for a company the size of Biocon where biosimilars are only part of the story.
What we're watching
- Revenue contribution from the new line, if disclosed.
- Demand growth for Semglee against Lantus in the EU.
- Any further capacity expansions at the Johor site.
The full read
Biocon's Semglee, already the cheaper alternative to Lantus in the EU, just got more manufacturing firepower. The EMA approved a new fill finish line at the Johor plant, with shipments starting Q2 FY27. The site has absorbed over $600 million in insulin investment. Yet for a company that posted ₹4,517 cr in March-quarter sales and carries a trailing P/E of 174.9, a capacity expansion without a disclosed value is a process item, not a pivot. It de-risks supply but does not rewrite the earnings story. Not yet.
Questions answered
- What exactly did the EMA approve?
- A new drug product fill finish line for Biocon's biosimilar insulin glargine, Semglee, at its Malaysian manufacturing facility in Johor.
- When will Biocon start supplying Europe from this line?
- Shipments are expected to commence in Q2 of fiscal 2027.
- How much has Biocon invested in its Johor insulin facility?
- Over $600 million over the years.
- What is the financial impact of this approval?
- The company did not disclose incremental capacity or financial impact. Analysts view it as likely modest relative to overall biosimilars earnings.
Biocon Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BIOCON →- 16 Jul 2026 · 8:44 AM IST EMA clears Biocon's new Semglee fill line in Malaysia
- 13d ago Mylan dumps its 5.64% Biocon stake in ₹4,000 cr open-market sale
- 34d ago Biocon scores MYR 225 mn insulin supply deal in Malaysia